http://www.pharmatimes.com/Article/10-09-29/AstraZeneca_begins_testing_RA_drug_fostamatinib_in_Ph_III.aspx Anglo-Swedish
drug giant AstraZeneca has kicked off a Phase III clinical trial of its
newly-acquired oral syk inhibitor fostamatinib, to assess its potential
as a novel treatment for rheumatoid arthritis. The drugmaker said it has now enrolled the first patient in
the study, which is looking at the use of fostamatinib - bought from
Rigel Pharmaceuticals in a deal worth up to .25 billion in February -
to treat patients who have had an inadequate response to disease
modifying anti-rheumatic drugs (DMARDs) such as methotrexate (MTX).
Copyright ArthritisInsight.com